Nektar Therapeutics Q3 2022 net loss narrows to $59M; cash at $546M, runway through mid-2025

NEKTAR THERAPEUTICS

2022-Q3 EPS reported -$1.65 revenue$70,032,000

Cash and investments at $546.4M at Sep 30, down from $628.2M at Q2 end; cash runway through mid-2025.
Net loss Q3 $59.0M ($0.31 per share) vs $129.7M ($0.70) year ago; revenue $23.6M (non-cash royalty).
R&D expense fell to $33.6M from $103.7M due to wind-down of bempegaldesleukin program.
Restructuring/impairment costs $124.3M year-to-date, including $58.5M non-cash lease/equipment impairment.
Pipeline: NKTR-358 (w/ Lilly) proof-of-concept in atopic dermatitis; NKTR-255 Phase 2 in large B-cell lymphoma planned.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NEKTAR THERAPEUTICS reported third quarter ended September 30, 2022 results: revenue $23.6 million, net income $59.0 million, EPS $0.31 basic and diluted loss per share.

Period: third quarter ended September 30, 2022
Revenue: $23.6 million
Net income: $59.0 million
EPS: $0.31 basic and diluted loss per share
Result: reported results

Exact text from the filing

lay the foundation for continued pipeline progress.” Summary of Financial Results Revenue, which primarily includes non-cash royalty revenue, in the third quarter of 2022 was $23.6 million as compared to $24.9 million in the third quarter of 2021. Revenue for the first nine months of 2022 was $70.0 million as compared to $76.9 million in the first nine months of

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-22-068992

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.